Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
TRASYLOL (aprotinin) is a serine protease inhibitor administered by injection to reduce surgical bleeding during cardiopulmonary bypass and other high-blood-loss procedures. It works by inhibiting fibrinolysis and platelet activation, thereby preserving blood coagulation during surgery. The drug is used as an adjunctive hemostatic agent in perioperative settings.
Product approaching loss of exclusivity with moderate competitive pressure (30%), suggesting declining team investment and potential headcount reduction or redeployment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Aprotinin US Special Access Protocol
Working on TRASYLOL offers limited career growth due to approaching loss of exclusivity and minimal job openings (0 linked positions). Roles focus on defending market share and managing decline rather than launching or expanding a product.
Worked on TRASYLOL at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.